IDEAYA Biosciences, Inc. (IDYA)

40,50 -1,03 (-2,48%) Alla chiusura: 04:00PM EDT

IDEAYA Biosciences, Inc.

7000 Shoreline Court
Suite 350
South San Francisco, CA 94080
United States
650 443 6209
https://www.ideayabio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 124

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Yujiro S. Hata	President, CEO & Director	912k	2,38M	1974
Mr. Andres Ruiz Briseno CPA	Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations	485,12k	N/D	1986
Dr. Michael A. White Ph.D.	Chief Scientific Officer	661,8k	N/D	1966
Mr. Jason S. Throne Esq., J.D.	Chief Legal Officer & Company Secretary	598,8k	903,73k	1972
Dr. Darrin M. Beaupre M.D., Ph.D.	Chief Medical Officer	665,58k	N/D	1967
Dr. Paul A. Barsanti Ph.D.	Chief Technology Officer	N/D	N/D	N/D
Mr. Mick O'Quigley	Chief of Staff & Clinical Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di IDEAYA Biosciences, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.